Capricor Therapeutics ISIN: US14070B3096 Forum: Aktien Thema: Hauptdiskussion

Noch ein paar aktuelle Infos zum Offering: "Capricor Therapeutics (NASDAQ: CAPR) priced an underwritten public offering of 6,000,000 common shares at $25.00 per share, with gross proceeds expected to be $150 million before fees. The company granted underwriters a 30-day option to purchase up to an additional 900,000 shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about December 8, 2025, subject to customary closing conditions. Net proceeds are intended for continued product development, manufacturing, working capital and general corporate purposes. The securities are offered under an effective Form S-3 shelf registration declared effective September 23, 2025."

✊✊

wer weiss das schon, ich vermute es läuft ähnlich wie bei cambium oder beyond

DAs bedeutet fǔr dich Bishin zu welchem Kurs ?

ich warte auf den squeeze

Denkt ihr hier wird es nochmal einen ordentlichen run geben ?

8 Mio Stück; gecovert wird hier noch nicht sein

Ich feier das

Und Aktie geht hoch

Verwässerung 15%

Kann von mir aus nun so weiter ziehen

Ziemlich viel Bewegung grad wieder seit 22 Uhr

sind wir schon

Kônnten noch ins grǔne drehen in der AH

Ja und? Das war erwartet worden; die brauchen ja jetzt Geld zum investieren.

SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the commencement of a proposed underwritten public offering of shares of its common stock. In addition, Capricor intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to 15% of the aggregate number of shares of its common stock sold in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Piper Sandler and Oppenheimer & Co. are acting as the joint book-running managers for the proposed public offering. The Company intends to use the net proceeds from the proposed offering for the continued development of its product candidates, manufacturing of its product candidates, working capital and general corporate purposes.